Urovant Sciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch UROV and buy or sell other stocks, ETFs, and their options commission-free!About UROV
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902.
CEOJames A. Robinson, Jr.
CEOJames A. Robinson, Jr.
Employees—
Employees—
HeadquartersLondon, Greater London
HeadquartersLondon, Greater London
Founded2017
Founded2017
Employees—
Employees—
UROV Key Statistics
Market cap531.75M
Market cap531.75M
Price-Earnings ratio-3.09
Price-Earnings ratio-3.09
Dividend yield—
Dividend yield—
Average volume222.74K
Average volume222.74K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$16.26
52 Week high$16.26
52 Week low$7.15
52 Week low$7.15
Stock Snapshot
Urovant Sciences(UROV) stock is priced at $16.24, giving the company a market capitalization of 531.75M. It carries a P/E multiple of -3.09.
On 2025-12-13, Urovant Sciences(UROV) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 222.74K.
Over the past 52 weeks, Urovant Sciences(UROV) stock has traded between a high of $16.26 and a low of $7.15.
Over the past 52 weeks, Urovant Sciences(UROV) stock has traded between a high of $16.26 and a low of $7.15.
People also own
Based on the portfolios of people who own UROV. This list is generated using Robinhood data, and it’s not a recommendation.